HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bunn, P. A. Articles by Kelly, K. Search for Related Content PubMed PubMed Citation Articles by Bunn, P. A., Jr. Articles by Kelly, K.

New Combinations in the Treatment of Lung Cancer^*

A Time for Optimism

^* From the University of Colorado Cancer Center, Denver, CO.

Correspondence to: Paul A. Bunn, Jr., MD, University of Colorado Cancer Center, Box B-188, 4200 E 9th Ave, Denver, CO 80262; e-mail: paul.bunn{at}uchsc.edu

Strides have been made in the treatment of lung cancer in the last decade that warrant a more optimistic outlook toward the disease. The recent development of several new agents with single-agent activity, including paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan, is important, and those agents offer even greater potential when they are used in combination chemotherapy regimens or in combined-modality programs. The experience to date with therapy results with these agents in the treatment of lung cancer is reviewed and is compared to results documented with the current standard treatments for lung cancer, namely, cisplatin and cisplatin-based combination regimens. Published and ongoing trials are outlined, and directions for future research and the future goals of lung cancer therapy are outlined. The availability of newer chemotherapeutic agents that are active in lung cancer has led to response rates as high as 40% in the treatment of non-small cell lung cancer. These drugs have been shown to be active in combination drug regimens as well as when combined with radiotherapy. Future research will focus on using these agents in two- and three-drug regimens as radiation sensitizers and in combination programs with new drugs and biological agents with apparent activity against this disease.

Key Words: cisplatin • combination therapy • docetaxel • gemcitabine • irinotecan • lung cancer • paclitaxel • response rates • survival • vinorelbine

This article has been cited by other articles:

				C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis JAMA, July 28, 2004; 292(4): 470 - 484. [Abstract] [Full Text] [PDF]

				K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, K. Goto, Y. Nishiwaki, T. Kodama, M. Suga, and A. Ochiai Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1691 - 1697. [Abstract] [Full Text] [PDF]

				P. Bonnette, P. Puyo, C. Gabriel, R. Giudicelli, J.-F. Regnard, M. Riquet, and P.-Y. Brichon Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases Chest, May 1, 2001; 119(5): 1469 - 1475. [Abstract] [Full Text] [PDF]